SARS-CoV-2 spike protein promotes inflammatory cytokine activation and aggravates rheumatoid arthritis, Cell Communication and Signaling

Background Coronavirus disease 2019 (COVID-19) induces inflammation, autoantibody production, and thrombosis, which are common symptoms of autoimmune diseases, including rheumatoid arthritis (RA). However, the effect of COVID-19 on autoimmune disease is not yet fully understood. Methods This study was performed to investigate the effects of COVID-19 on the development and progression of RA using a collagen-induced arthritis (CIA) animal model. Human fibroblast-like synoviocytes (FLS) were transduced with lentivirus carrying the SARS-CoV-2 spike protein gene in vitro, and the levels of inflammatory cytokine and chemokine expression were measured. For in vivo experiments, CIA mice were injected with the gene encoding SARS-CoV-2 spike protein, and disease severity, levels of autoantibodies, thrombotic factors, and inflammatory cytokine and chemokine expression were assessed. In the in vitro experiments, the levels of inflammatory cytokine and chemokine expression were significantly increased by overexpression of SARS-CoV-2 spike protein in human FLS. Results The incidence and severity of RA in CIA mice were slightly increased by SARS-CoV-2 spike protein in vivo. In addition, the levels of autoantibodies and thrombotic factors, such as anti-CXC chemokine ligand 4 (CXCL4, also called PF4) antibodies and anti-phospholipid antibodies were significantly increased by SARS-CoV-2 spike protein. Furthermore, tissue destruction and inflammatory cytokine level in joint tissue were markedly increased in CIA mice by SARS-CoV-2 spike protein. Conclusions The results of the present study suggested that COVID-19 accelerates the development and progression of RA by increasing inflammation, autoantibody production, and thrombosis. Video Abstract

SGK1 negatively regulates inflammatory immune responses and protects against alveolar bone loss through modulation of TRAF3 activity - Journal of Biological Chemistry

Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19

Frontiers Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?

SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway

Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19

FOXP3 Antibody PE 12-5773-82 from Thermo Fisher Scientific

Cytokine Storm and its Implication in Coronavirus disease 2019 (COVID-19)

FOXP3 Antibody PE 12-5773-82 from Thermo Fisher Scientific

Viruses: What triggers inflammation in COVID-19?

CXCL4/PF4 ELISA DY595 from R&D Systems, a Bio-Techne Brand